Nkarta

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

To target the root causes of diseases with engineered natural killer cell therapeutics to improve the lives of patients.

To create a diverse portfolio of potential life-saving therapies delivering targeted and durable clinical benefit to patients.

In 2017, Nkarta was recognized as the 'Startup of the Year' by FierceBiotech. In 2020, Nkarta was awarded the CIRM and Helmsley Collaboration for Early Translational programs to optimize therapeutics for use in clinical trials.